Abbott Laboratories vs TotalEnergies SE — how do they compare? Abbott Laboratories trades at $111 (market cap $187.95B), while TotalEnergies SE trades at $87.8 (market cap $196.06B). The key difference: Abbott Laboratories and TotalEnergies SE are close in size by market cap, and TotalEnergies SE pays the higher dividend (4.82%). Which is the better fit depends on your goals.
| ABT | TTE | |
|---|---|---|
Market Cap | $187.95B | $196.06B |
Sector | Health | Energy |
52-Week High | $136.62 | $93.60 |
52-Week Low | $82.57 | $57.39 |
Enterprise Value | $214.96B | $227.06B |
Dividend Yield | 2.32% | 4.82% |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
TotalEnergies (TTE) trades at $87.49, down 0.53% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $94.00. The company reported mixed recent earnings, missing in Q4 2025 but beating in Q1 and Q2 2026, while revenue has declined from $263.3B in 2022 to $182.3B in 2025. Recent strategic moves include acquiring Shell's European onshore renewables business and developing the Cronos gas field in Cyprus, signaling a shift toward integrated energy.
TTE presents a value opportunity with a low P/E of 11.01 and strong cash flow, but faces headwinds from declining revenue and regulatory climate litigation. The stock's upside is supported by analyst bullishness and dividend payments, yet investors must weigh energy transition execution risks against its current attractive valuation.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →TotalEnergies is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.5 million barrels of liquids and 7.2 billion cubic feet of natural gas per day. At year-end 2020, reserves stood at 12.1 billion barrels of oil equivalent, 45% of which are liquids. During 2021, it had LNG sales of 42 Mt. The company owns interests in refineries with capacity of nearly 1.8 million barrels a day, primarily in Europe, distributes refined products in 65 countries, and manufactures commodity and specialty chemicals. It also holds a 19% interest in Russian oil company Novatek. At year-end, its gross installed renewable power generation capacity was 10.3 GW.
Read more on TTE →